Study on the application of paclitaxel liposome combined with carboplatin and tirellizumab in patients with lung squamous cell carcinoma
Objective To investigate the application of paclitaxel liposome combined with carboplatin and tirellizumab in patients with lung squamous cell carcinoma.Methods Fifty patients with lung squamous cell carcinoma enrolled in a hospital from 2021 to 2022 were selected and divided into the control group(n=25)and the observation group(n=25)according to random number method.The control group was treated with paclitaxel liposome combined with carboplatin,and the observation group was treated with tirilizumab on the basis of the control group.The tumor marker levels,quality of life,and toxic and side effects of the two groups were compared,and the clinical efficacy of the patients was evaluated.Results The total effective rate of observation group was higher than that of the control group(P＜0.05).After treatment,serum levels of SCC,CYFRA21-1,CA125 and CEA in the two groups were decreased(P＜0.05),and observation group was lower than control group(P＜0.05).After treatment,the social/family life,daily life,activity ability,emotion,other factors and total scores of both groups were increased(P＜0.05),and the observation group was higher than those of the control group(P＜0.05).Compared with the control group,the toxic and side effects were not significantly increased in the observation group(P＞0.05).Conclusion The treatment of lung squamous cell carcinoma patients with paclitaxel liposome combined with carboplatin and tirellizumab is effective,can control the level of serum tumor markers,improve the quality of life,and the safety is relatively guaranteed.
Lung squamous cell carcinomaPaclitaxel LiposomeTirellizumabCarboplatinApplied research
NETL
NSTL
万方数据
